PET/CT and Paraneoplastic Syndromes: A Comprehensive Review
Cancers · 13.08.2025 · 17 (16) · 2637
DOI: 10.3390/cancers17162637 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 13.08.2025. Verfasst von Motaz Daraghma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Saint Luke's Hospital of Kansas City, University of Missouri-Kansas City, Kansas City, MO 64110, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Paraneoplastic syndromes (PNSs) are pathologic conditions produced by neoplasms not attributable to tumor invasion or metastasis. The clinical manifestations of PNSs can precede the diagnosis; these symptoms may serve as early indicators of underlying malignancy. Standard imaging modalities, such as computed tomography (CT) and magnetic resonance imaging (MRI), have limited sensitivity in detecting small or early-stage PNS-associated tumors. FDG PET/CT identifies hypermetabolic lesions suggestive of malignancy and, therefore, facilitates early diagnosis, refined treatment planning, and potentially prolonged patient survival. This review evaluates the diagnostic accuracy, clinical utility, and emerging role of FDG PET/CT in detecting occult malignancies. Syndrome-targeted applications discussed include limbic encephalitis, cerebellar degeneration, Lambert-Eaton myasthenic syndrome, Cushing’s syndrome, hypercalcemia of malignancy, dermatomyositis, and tumor-induced osteomalacia. In addition, the limitations of FDG PET/CT, including false-positive or false-negative findings, are reviewed, while newer PET tracers, like 68Ga-DOTATATE, are also highlighted. Ultimately, FDG PET/CT has transformed clinical decision-making, enabling more timely interventions and improved patient management in the context of PNSs. Future directions in imaging, including PET/MRI and ongoing refinements in tracer design, promise to further enhance diagnostic precision, and therapeutic outcomes are also discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Saint Luke's Hospital of Kansas City, University of Missouri-Kansas City, Kansas City, MO 64110, USA.
- Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.
- Nuclear Medicine Unit, Department of Biomedical, Dental Sciences and Morpho-Functional Imaging, Messina University, 98122 Messina, Italy.
- Department of Radiology, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA 90089, USA.
ORCID-Profile: Riccardo Laudicella, Ahmad Shariftabrizi
Förderung
- NCI NIH HHS
Zitieren
APA
Daraghma, M., Aswani, Y., Jain, S., Laudicella, R., Gholamrezanezhad, A., Menda, Y., & Shariftabrizi, A. (2025). PET/CT and Paraneoplastic Syndromes: A Comprehensive Review. Cancers, 17(16), 2637. https://doi.org/10.3390/cancers17162637
Vancouver
Daraghma M, Aswani Y, Jain S, Laudicella R, Gholamrezanezhad A, Menda Y, et al. PET/CT and Paraneoplastic Syndromes: A Comprehensive Review. Cancers. 2025;17(16):2637. doi:10.3390/cancers17162637
BibTeX
@article{Daraghma2025,
author = {Daraghma, Motaz and Aswani, Yashant and Jain, Sanchay and Laudicella, Riccardo and Gholamrezanezhad, Ali and Menda, Yusuf and Shariftabrizi, Ahmad},
title = {PET/CT and Paraneoplastic Syndromes: A Comprehensive Review},
journal = {Cancers},
year = {2025},
volume = {17},
number = {16},
pages = {2637},
doi = {10.3390/cancers17162637}
}
EUVIMED